A Pilot Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 in the Same Group of Primary Prostate Cancer Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:
• histologically confirmed untreated primary prostate cancer patients;
• 68Ga-PSMA-11 and 68Ga-P16-093 PET/CT within a week;
• signed written consent.
Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Zhaohui Zhu, MD
13611093752@163.com
86-13611093752
Backup
Guochang Wang, MD
guochang1007@163.com
86-18516822732
Time Frame
Start Date: 2022-04-15
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 50
Treatments
Experimental: 68Ga-P16-093 and 68Ga-PSMA-11 PET/ CT scan
Patients of Prostate cancer PET/CT imaging: In two consecutive days, each patient underwent whole-body PET/CT scan after intravenous administration of 68Ga-P16-093 and 68Ga-PSMA-11, respectively.
Related Therapeutic Areas
Sponsors
Leads: Peking Union Medical College Hospital